ArticleFrontiers in cardiovascular medicine2026
Linking liver fibrosis to cardiac structure, function, and heart disease: a community-based fibrosis-4 index study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Fibrosis-4 Index (FIB-4) is a non-invasive tool used to assess advanced liver fibrosis. Although liver fibrosis has been linked to heart disease, its relationship with cardiac structure and function remains unclear. Objectives: This study examined associations of FIB-4 with incident heart disease and cardiac morpho-functional phenotypes and explored whether cardiac phenotypes statistically accounted for part of the association. Methods: In this prospective cohort study using the UK Biobank, 416,001 participants without known heart or liver disease at baseline (mean age 56.15 ± 8.09 years; 55.78% female) were followed for up to 17 years. FIB-4, calculated from age, AST, ALT, and platelet count, was analyzed continuously and using a high-risk threshold of >2.67. Incident coronary heart disease, cardiac arrhythmias (CA), and heart failure (HF) were identified from linked records. A subset of 33,927 participants underwent cardiovascular magnetic resonance (CMR) imaging a median of 10.20 years after baseline. Results: Over a median follow-up of 14.61 years, 57,207 participants (13.75%) developed heart disease. Higher FIB-4 was associated with CA (HR = 1.32, 95% CI 1.24-1.41), HF (HR = 1.29, 95% CI 1.14-1.47), greater LV mass ( Conclusion: Elevated FIB-4 was associated with incident CA and HF and with adverse CMR phenotypes. Exploratory pathway results were consistent with indirect pathways through cardiac remodeling, but the observational design and single CMR assessment preclude causal or temporal interpretation. FIB-4 may help identify people at higher cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.